INVEGA SUSTENNA® Common Dosing and Administration Topics

Switching from Other Antipsychotics

From Oral INVEGA® ER to INVEGA SUSTENNA® – General Overview

Consistent with the INVEGA SUSTENNA® Prescribing Information:

  • There are no systematically collected data to specifically address switching patients with schizoaffective disorder from other antipsychotics to INVEGA SUSTENNA®, or concerning concomitant administration with other antipsychotics.
  • Previous oral antipsychotics can be gradually discontinued at the time of initiation of treatment with INVEGA SUSTENNA®. Recommended initiation of INVEGA SUSTENNA® is with a dose of 234 mg followed by 156 mg one week later, both administered in the deltoid muscle. Patients previously stabilized on different doses of oral INVEGA® ER can attain similar paliperidone steady-state exposure during maintenance treatment with INVEGA SUSTENNA® monthly doses as depicted in the Table from the INVEGA SUSTENNA® Prescribing Information.

Table: Doses of INVEGA® and INVEGA SUSTENNA® needed to attain similar steady-state palliperidone exposure during maintenance treatment

Formulation INVEGA® Exteneded-Release Tablet INVEGA SUSTENNA® Injection
Dosing Frequency Once Daily Once every 4 weeks
Dose (mg) 12 234
9 156
6 117
3 39-78

For illustrative displays of this dosing scenario, please click the link(s) below.

Switching from Oral INVEGA® ER for Schizoaffective Disorder

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:


  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants


  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm


Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel